Comparative Effects of Pulsatile and Nonpulsatile Flow on Plasma Fibrinolytic Balance in Pediatric Patients Undergoing Cardiopulmonary Bypass

Artificial Organs

Volumn 38, Issue 1, 2014, Pages 28-33

  Aĝirbaşli, Mehmet A ^a   Song, Jianxun ^b   Lei, Fengyang ^b   Wang, Shigang ^c   Kunselman, Allen R ^b   Clark, Joseph B ^c   Myers, John L ^c   Ündar, Akif ^c,d  

^a Section of Pediatric Epileptology and Video EEG Lab Acibadem   (Turkey)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d The Pennsylvania State University   (United States)

Author keywords

Cardiopulmonary bypass; Fibrinolytic balance; Plasminogen activator inhibitor 1; Pulsatile flow; Tissue plasminogen activator

Indexed keywords

ANTIGENS; PULSATILE FLOW; TISSUE;

ACTIVATOR CONCENTRATION; CARDIOPULMONARY BYPASS; ENDOGENOUS INHIBITOR; FIBRINOLYTIC BALANCE; PATHOLOGICAL RESPONSE; PEDIATRIC PATIENTS; PLASMA SAMPLES; PLASMINOGEN ACTIVATOR INHIBITOR-1; PULSATILES; TISSUE PLASMINOGEN ACTIVATOR;

PEDIATRICS;

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BRAIN PERFUSION; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; FLOW KINETICS; HUMAN; MALE; NONPULSATILE FLOW; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSATILE FLOW; SCHOOL CHILD;

CARDIOPULMONARY BYPASS; FIBRINOLYTIC BALANCE; PLASMINOGEN ACTIVATOR INHIBITOR-1; PULSATILE FLOW; TISSUE PLASMINOGEN ACTIVATOR;

CARDIOPULMONARY BYPASS; CHILD, PRESCHOOL; FEMALE; FIBRINOLYSIS; HUMANS; INFANT; MALE; PLASMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PULSATILE FLOW; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84891902856     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12182     Document Type: Article

References (32)

1. Marino BS, Lipkin PH, Newburger, JW, etal. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management (a scientific statement from the American Heart Association). Circulation 2012;126:1143-1172.
2. Su X, Ündar A. Brain protection during pediatric cardiopulmonary bypass. Artif Organs 2010;34:E91-102.
3. Ishibashi N, Scafidi J, Murata A, etal. White matter protection in congenital heart surgery. Circulation 2012;125:859-871.
4. Mahle WT, Tavani F, Zimmerman RA, etal. An MRI study of neurological injury before and after congenital heart surgery. Circulation 2002;106(Suppl. I):I-109-14.
5. Dent CL, Spaeth JP, Jones BV, etal. Brain magnetic resonance imaging abnormalities after the Norwood procedure using regional cerebral perfusion. J Thorac Cardiovasc Surg 2006;131:190-197.
6. Knottnerus IL, Govers-Riemslag JW, Hamulyak K, etal. Endothelial activation in lacunar stroke subtypes. Stroke 2010;41:1617-1622.
7. Teesalu T, Kulla A, Simisker A, etal. Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost 2004;92:358-368.
8. Van De Craen B, Declerck PJ, Gils A. The biochemistry, physiology and pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res 2012;130:576-585.
9. Tjärnlund-Wolf A, Brogren H, Lo EH, Wang X. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke 2012;43:2833-2839.
10. Tohgi H, Utsugisawa K, Yoshimura M, Nagane Y, Ukitsu M. Local variation in expression of pro- and antithrombotic factors in vascular endothelium of human autopsy brain. Acta Neuropathol 1999;98:111-118.
11. Myohanen H, Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 2004;61:2840-2858.
12. Soeda S, Koyanagi S, Kuramoto Y, etal. Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system. Thromb Haemost 2008;100:1014-1020.
13. Benchenane K, Berezowski V, Ali C, etal. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005;111:2241-2249.
14. Wang X, Rosell A, Lo EH. Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy. CNS Neurol Disord Drug Targets 2008;7:235-242.
15. Agirbasli M, Nguyen ML, Win K, etal. Inflammatory and hemostatic response to cardiopulmonary bypass in pediatric population: feasibility of serological testing of multiple biomarkers. Artif Organs 2010;34:987-995.
16. Rogerson A, Guan Y, Kimatian SJ, etal. Transcranial Doppler ultrasonography: a reliable method of monitoring pulsatile flow during cardiopulmonary bypass in infants and young children. J Thorac Cardiovasc Surg 2010;139:e80-82.
17. Su XW, Guan Y, Barnes M, Clark JB, Myers JL, Ündar A. Improved cerebral oxygen saturation and blood flow pulsatility with pulsatile perfusion during pediatric cardiopulmonary bypass. Pediatr Res 2011;70:181-185.
18. Ündar A, Palanzo D, Qiu F, etal. Benefits of pulsatile flow in pediatric cardiopulmonary bypass procedures: from conception to conduction [Invited Review]. Perfusion 2011;26:35-39.
19. Alkan-Bozkaya T, Akçevin A, Türkoǧlu H, Ündar A. Impact of pulsatile perfusion on clinical outcomes of neonates & infants with complex pathologies undergoing cardiopulmonary bypass procedures. Artif Organs 2013;37:82-86.
20. Ündar A. Pulsatile versus non-pulsatile cardiopulmonary bypass procedures in neonates and infants: from bench to clinical practice [Invited Editorial]. ASAIO J 2005;51:vi-x.
21. O'Neil MP, Fleming JC, Badhwar A, Guo LR. Pulsatile versus nonpulsatile flow during cardiopulmonary bypass: microcirculatory and systemic effects. Ann Thorac Surg 2012;94:2046-2053.
22. Elbers PW, Wijbenga J, Solinger F, etal. Direct observation of the human microcirculation during cardiopulmonary bypass: effects of pulsatile perfusion. J Cardiothorac Vasc Anesth 2011;25:250-255.
23. Agirbasli M, Ündar A. Monitoring biomarkers after pediatric heart surgery: a new paradigm on the horizon. Artif Organs 2013;37:10-15.
24. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
25. Teesalu T, Kulla A, Asser T, Koskiniemi M, Vaheri A. Tissue plasminogen activator as a key effector in neurobiology and neuropathology. Biochem Soc Trans 2002;30:183-189.
26. Varjú I, Sótonyi P, Machovich R, etal. Hindered dissolution of fibrin formed under mechanical stress. J Thromb Haemost 2011;9:979-986.
27. Kim JW, Lee SH, Ko HM, etal. Biphasic regulation of tissue plasminogen activator activity in ischemic rat brain and in cultured neural cells: essential role of astrocyte-derived plasminogen activator inhibitor-1. Neurochem Int 2011;58:423-433.
28. Creighton DE, Robertson CM, Sauve RS, etal. Neurocognitive, functional, and health outcomes at 5 years of age for children after complex cardiac surgery at 6 weeks of age or younger. Pediatrics 2007;120:e478-486.
29. Andropoulos DB, Hunter JV, Nelson DP, etal. Brain immaturity is associated with brain injury before and after neonatal cardiac surgery with high-flow bypass and cerebral oxygenation monitoring. J Thorac Cardiovasc Surg 2010;139:543-556.
30. Andropoulos DB, Brady KM, Easley RB, Fraser CD Jr. Neuroprotection in pediatric cardiac surgery: what is on the horizon? Prog Pediatr Cardiol 2010;29:113-122.
31. Nagai N, Suzuki Y, Van Hoef B, Lijnen HR, Collen D. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost 2005;3:1379-1384.
32. Lemarchant S, Docagne F, Emery E, Vivien D, Ali C, Rubio M. tPA in the injured central nervous system: different scenarios starring the same actor? Neuropharmacology 2012;62:749-756.